Joseph M Collins1, Danxin Wang1. 1. Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Abstract
OBJECTIVES: The function and expression of cytochrome P450 (CYP) drug metabolizing enzymes is highly variable, greatly affecting drug exposure, and therapeutic outcomes. The expression of these enzymes is known to be controlled by many transcription factors (TFs), including ligand-free estrogen receptor alpha (ESR1, in the absence of estrogen). However, the relationship between the expression of ESR1, other TFs, and CYP enzymes in human liver is still unclear. METHODS: Using real-time PCR, we quantified the mRNA levels of 12 CYP enzymes and nine TFs in 246 human liver samples from European American (EA, n = 133) and African American (AA, n = 113) donors. RESULTS: Our results showed higher expression levels of ESR1 and six CYP enzymes in EA than in AA. Partial least square regression analysis showed that ESR1 is the top-ranking TF associating with the expression of eight CYP enzymes, six of which showed racial difference in expression. Conversely, four CYP enzymes without racial difference in expression did not have ESR1 as a top-ranking TF. These results indicate that ESR1 may contribute to variation in CYP enzyme expression between these two ancestral backgrounds. CONCLUSIONS: These results are consistent with our previous study showing ESR1 as a master regulator for the expression of several CYP enzymes. Therefore, factors affecting ESR1 expression may have broad influence on drug metabolism through altered expression of CYP enzymes.
OBJECTIVES: The function and expression of cytochrome P450 (CYP) drug metabolizing enzymes is highly variable, greatly affecting drug exposure, and therapeutic outcomes. The expression of these enzymes is known to be controlled by many transcription factors (TFs), including ligand-free estrogen receptor alpha (ESR1, in the absence of estrogen). However, the relationship between the expression of ESR1, other TFs, and CYP enzymes in human liver is still unclear. METHODS: Using real-time PCR, we quantified the mRNA levels of 12 CYP enzymes and nine TFs in 246 human liver samples from European American (EA, n = 133) and African American (AA, n = 113) donors. RESULTS: Our results showed higher expression levels of ESR1 and six CYP enzymes in EA than in AA. Partial least square regression analysis showed that ESR1 is the top-ranking TF associating with the expression of eight CYP enzymes, six of which showed racial difference in expression. Conversely, four CYP enzymes without racial difference in expression did not have ESR1 as a top-ranking TF. These results indicate that ESR1 may contribute to variation in CYP enzyme expression between these two ancestral backgrounds. CONCLUSIONS: These results are consistent with our previous study showing ESR1 as a master regulator for the expression of several CYP enzymes. Therefore, factors affecting ESR1 expression may have broad influence on drug metabolism through altered expression of CYP enzymes.
Authors: Zhaoyi Wang; Xintian Zhang; Peng Shen; Brian W Loggie; Yunchao Chang; Thomas F Deuel Journal: Proc Natl Acad Sci U S A Date: 2006-06-05 Impact factor: 11.205
Authors: J Steven Leeder; Roger Gaedigk; Kenda A Marcucci; Andrea Gaedigk; Carrie A Vyhlidal; Bradley P Schindel; Robin E Pearce Journal: J Pharmacol Exp Ther Date: 2005-04-21 Impact factor: 4.030
Authors: Biola M Javierre; Oliver S Burren; Steven P Wilder; Roman Kreuzhuber; Steven M Hill; Sven Sewitz; Jonathan Cairns; Steven W Wingett; Csilla Várnai; Michiel J Thiecke; Frances Burden; Samantha Farrow; Antony J Cutler; Karola Rehnström; Kate Downes; Luigi Grassi; Myrto Kostadima; Paula Freire-Pritchett; Fan Wang; Hendrik G Stunnenberg; John A Todd; Daniel R Zerbino; Oliver Stegle; Willem H Ouwehand; Mattia Frontini; Chris Wallace; Mikhail Spivakov; Peter Fraser Journal: Cell Date: 2016-11-17 Impact factor: 41.582